N⁴-(3-ethoxyphenyl)pyrimidine-2,4,6-triamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N⁴-(3-ethoxyphenyl)pyrimidine-2,4,6-triamine
• 英文别名: 4-N-(3-ethoxyphenyl)pyrimidine-2,4,6-triamine
• 化学式: C₁₂H₁₅N₅O
• mdl: MFCD25028583
• 分子量: 245.284
• InChiKey: KSQJCMHFEGOPIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  99.1
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N⁴-(3-ethoxyphenyl)pyrimidine-2,4,6-triamine 、 对苯醌 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 以5%的产率得到2-amino-4-((3-ethoxyphenyl)amino)-9H-pyrimido[4,5-b]indol-6-ol
  参考文献：
  名称：

  Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance

  摘要：

  With ongoing resistance problems against the marketed EGFR inhibitors having a quinazoline core scaffold there is a need for the development of novel inhibitors having a modified scaffold and, thus, expected lower EGFR resistance problems. An additional problem concerning EGFR inhibitor resistance is an observed heterodimerization of EGFR with PDGFR-beta that neutralises the sole inhibitor activity towards EGFR. We developed novel pyrimido[4,5-b] indoles with varied substitution patterns at the 4-anilino residue to evaluate their EGFR and PDGFR-beta inhibiting properties. We identified dual inhibitors of both EGFR and PDGFR-beta in the nanomolar range which have been initially screened in cancer cell lines to prove a benefit of both EGFR and PDGFR-beta inhibition.

  DOI：

  10.1080/14756366.2017.1370583
• 作为产物：
  描述：

  2,4-二氨基-6-氯嘧啶 、 间氨基苯乙醚 以77%的产率得到N⁴-(3-ethoxyphenyl)pyrimidine-2,4,6-triamine
  参考文献：
  名称：

  Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance

  摘要：

  With ongoing resistance problems against the marketed EGFR inhibitors having a quinazoline core scaffold there is a need for the development of novel inhibitors having a modified scaffold and, thus, expected lower EGFR resistance problems. An additional problem concerning EGFR inhibitor resistance is an observed heterodimerization of EGFR with PDGFR-beta that neutralises the sole inhibitor activity towards EGFR. We developed novel pyrimido[4,5-b] indoles with varied substitution patterns at the 4-anilino residue to evaluate their EGFR and PDGFR-beta inhibiting properties. We identified dual inhibitors of both EGFR and PDGFR-beta in the nanomolar range which have been initially screened in cancer cell lines to prove a benefit of both EGFR and PDGFR-beta inhibition.

  DOI：

  10.1080/14756366.2017.1370583

文献信息

• Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
  作者：Tim Fischer、Abdulkarim Najjar、Frank Totzke、Christoph Schächtele、Wolfgang Sippl、Christoph Ritter、Andreas Hilgeroth

  DOI：10.1080/14756366.2017.1370583

  日期：2018.1.1

  With ongoing resistance problems against the marketed EGFR inhibitors having a quinazoline core scaffold there is a need for the development of novel inhibitors having a modified scaffold and, thus, expected lower EGFR resistance problems. An additional problem concerning EGFR inhibitor resistance is an observed heterodimerization of EGFR with PDGFR-beta that neutralises the sole inhibitor activity towards EGFR. We developed novel pyrimido[4,5-b] indoles with varied substitution patterns at the 4-anilino residue to evaluate their EGFR and PDGFR-beta inhibiting properties. We identified dual inhibitors of both EGFR and PDGFR-beta in the nanomolar range which have been initially screened in cancer cell lines to prove a benefit of both EGFR and PDGFR-beta inhibition.